20 Aug 2018 09:30
Silence Therapeutics Announces Board Change
20 AUGUST 2018
Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases, announces today that Dr. Annalisa Jenkins is leaving her role as executive Chair and Director of the Company with immediate effect. Dr. Andy Richards, CBE, a non-executive Director of Silence Therapeutics since September 2016, is today assuming the role of non-executive Chair in an interim capacity to ensure a smooth transition. The Company has commenced a process to appoint a new Chair and will report further in due course.
Dr. David Horn Solomon, Chief Executive Officer of Silence, commented: "On behalf of the Company and my colleagues on the Board, we thank Annalisa Jenkins for her energetic and dedicated service to Silence Therapeutics during the past year. In a short period of time, Annalisa has been responsible for upgrading our R&D operations, and reshaping the company strategy. We wish her well with her portfolio of Board and non-Board roles and her future endeavours. Silence is now in a much better position to compete in the newly approved drug modality of RNAi, and we are excited to continue our drug development based upon our proprietary platform."
Enquiries:
Silence Therapeutics plc David Horn Solomon, Chief Executive Officer Dr. Andy Richards CBE, Interim Chair David Ellam, Chief Financial Officer
| Tel: +44 (0) 20 3457 6900 |
Peel Hunt LLP (Nominated Adviser and Broker) James Steel/ Oliver Jackson
| Tel: +44 (0) 20 7418 8900 |
European IR Consilium Strategic Communications Mary-Jane Elliott, Angela Gray silencetherapeutics@consilium-comms.com
| Tel: +44 (0) 20 3709 5700 |
US IR Burns McClellan John Grimaldi silence.therapeutics@burnsmc.com
| Tel: +1 (212) 213 0006 |
Notes to Editors
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. For more information, please visit: http://www.silence-therapeutics.com/